ME1 and fatty liver disease: Results support the premise that, in a mouse model of obesity, ME1 is an important physiological regulator of crosstalk among multiple signaling pathways, regardless of gender, suggesting its potential value as a targeted therapy for obesity, diabetes, fatty liver disease, and cancer in humans.